secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088689
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q2 revenue $114.3M (+118% YoY), net income $12.2M, raises FY guidance
--------------------------------------------------------------------------------

- Revenue $114.3M (+118% YoY); net income $12.2M ($0.35 diluted EPS) vs net loss $1.0M.
- Gross margin 61% (down from 70% YoY) due to higher service revenue mix.
- Operating expenses $56.8M (incl $7.3M stock comp) vs $37.6M prior year; driven by R&D and growth.
- Raises FY2024 revenue guidance to $425M-$445M (76%-84% growth) from prior $390M-$400M.
- Cash $362.8M as of June 30; owned 15 aircraft, purchased 2 more in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024088689/0000950170-24-088689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024088689/tmdx-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer